O	O	0	8	Selenium	Selenium	B-NP	NN	O	0	ROOT	O
O	O	8	9	-	-	B-PP	HYPH	O	1	NMOD	O
O	O	9	17	mediated	mediate	B-NP	VBN	O	4	NMOD	O
O	O	18	28	inhibition	inhibition	I-NP	NN	O	2	PMOD	O
O	O	29	31	of	of	B-PP	IN	O	4	NMOD	O
T4	B-Entity	32	45	transcription	transcription	B-NP	NN	B-protein	7	NMOD	B-protein
T4	I-Entity	46	52	factor	factor	I-NP	NN	I-protein	11	NMOD	I-protein
T4	I-Entity	53	55	NF	NF	I-NP	NN	B-protein	11	NMOD	B-protein
T4	I-Entity	55	56	-	-	B-NP	HYPH	I-protein	11	NMOD	I-protein
T4	I-Entity	56	61	kappa	kappa	I-NP	NN	I-protein	11	NMOD	I-protein
T4	I-Entity	62	63	B	B	I-NP	NN	I-protein	18	NMOD	I-protein
O	O	64	67	and	and	O	CC	O	18	NMOD	O
T5	B-Entity	68	71	HIV	HIV	B-NP	NN	B-DNA	17	NMOD	B-DNA
T5	I-Entity	71	72	-	-	B-NP	HYPH	I-DNA	17	NMOD	I-DNA
T5	I-Entity	72	73	1	1	I-NP	CD	I-DNA	17	NMOD	I-DNA
T5	I-Entity	74	77	LTR	LTR	I-NP	NN	I-DNA	17	NMOD	I-DNA
T5	I-Entity	78	86	promoter	promoter	I-NP	NN	I-DNA	18	NMOD	I-DNA
O	O	87	95	activity	activity	I-NP	NN	O	5	PMOD	O
O	O	95	96	.	.	O	.	O	1	P	O

O	O	98	101	The	The	B-NP	DT	O	8	NMOD	O
T6	B-Entity	102	112	eukaryotic	eukaryotic	I-NP	JJ	O	8	NMOD	O
T6	I-Entity	113	126	transcription	transcription	I-NP	NN	O	8	NMOD	O
T6	I-Entity	127	133	factor	factor	I-NP	NN	O	8	NMOD	O
T6	I-Entity	134	136	NF	NF	I-NP	NN	B-protein	8	NMOD	B-protein
T6	I-Entity	136	137	-	-	B-NP	HYPH	I-protein	8	NMOD	I-protein
T6	I-Entity	137	142	kappa	kappa	I-NP	NN	I-protein	8	NMOD	I-protein
T6	I-Entity	143	144	B	B	I-NP	NN	I-protein	9	SUB	I-protein
O	O	145	147	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	148	156	involved	involve	I-VP	VBN	O	9	VC	O
O	O	157	159	in	in	B-PP	IN	O	10	VMOD	O
O	O	160	163	the	the	B-NP	DT	O	14	NMOD	O
O	O	164	173	inducible	inducible	I-NP	JJ	O	14	NMOD	O
O	O	174	184	expression	expression	I-NP	NN	O	11	PMOD	O
O	O	185	187	of	of	B-PP	IN	O	14	NMOD	O
O	O	188	195	various	various	B-NP	JJ	O	15	PMOD	O
T7	B-Entity	196	208	inflammatory	inflammatory	I-NP	JJ	B-DNA	18	NMOD	B-DNA
T7	I-Entity	209	214	genes	gene	I-NP	NNS	I-DNA	16	NMOD	I-DNA
O	O	215	217	as	as	B-CONJP	RB	O	14	NMOD	O
O	O	218	222	well	well	I-CONJP	RB	O	19	DEP	O
O	O	223	225	as	as	I-CONJP	IN	O	19	DEP	O
O	O	226	228	in	in	B-PP	IN	O	19	PMOD	O
O	O	229	232	HIV	HIV	B-NP	NN	O	26	NMOD	O
O	O	232	233	-	-	B-NP	HYPH	O	26	NMOD	O
O	O	233	234	1	1	I-NP	CD	O	26	NMOD	O
O	O	235	246	replication	replication	I-NP	NN	O	22	PMOD	O
O	O	246	247	.	.	O	.	O	9	P	O

O	O	248	258	Activation	Activation	B-NP	NN	O	7	SUB	O
O	O	259	261	of	of	B-PP	IN	O	1	NMOD	O
T8	B-Entity	262	264	NF	NF	B-NP	NN	B-protein	6	NMOD	B-protein
T8	I-Entity	264	265	-	-	B-NP	HYPH	I-protein	6	NMOD	I-protein
T8	I-Entity	265	270	kappa	kappa	I-NP	NN	I-protein	6	NMOD	I-protein
T8	I-Entity	271	272	B	B	I-NP	NN	I-protein	2	PMOD	I-protein
O	O	273	275	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	276	283	induced	induce	I-VP	VBN	O	7	VC	O
O	O	284	286	by	by	B-PP	IN	O	8	VMOD	O
O	O	287	298	prooxidants	prooxidant	B-NP	NNS	O	13	NMOD	O
O	O	299	302	and	and	O	CC	O	13	NMOD	O
O	O	303	310	several	several	B-NP	JJ	O	13	NMOD	O
O	O	311	318	stimuli	stimulus	I-NP	NNS	O	9	PMOD	O
O	O	319	328	eliciting	elicit	B-VP	VBG	O	13	NMOD	O
O	O	329	338	oxidative	oxidative	B-NP	JJ	O	16	NMOD	O
O	O	339	345	stress	stress	I-NP	NN	O	14	OBJ	O
O	O	345	346	,	,	O	,	O	13	P	O
O	O	347	351	such	such	B-PP	JJ	O	19	PMOD	O
O	O	352	354	as	as	I-PP	IN	O	13	NMOD	O
O	O	355	364	cytokines	cytokine	B-NP	NNS	B-protein	28	NMOD	B-protein
O	O	364	365	,	,	O	,	O	28	P	O
O	O	366	384	lipopolysaccharide	lipopolysaccharide	B-NP	NN	O	28	NMOD	O
O	O	384	385	,	,	O	,	O	28	P	O
O	O	386	388	UV	UV	B-NP	NN	O	25	NMOD	O
O	O	389	400	irradiation	irradiation	I-NP	NN	O	28	NMOD	O
O	O	401	404	and	and	O	CC	O	28	NMOD	O
O	O	405	410	other	other	B-NP	JJ	O	28	NMOD	O
O	O	411	420	mediators	mediator	I-NP	NNS	O	19	PMOD	O
O	O	420	421	.	.	O	.	O	7	P	O

O	O	422	429	Various	Various	B-NP	JJ	O	2	NMOD	O
O	O	430	442	antioxidants	antioxidant	I-NP	NNS	O	3	SUB	O
O	O	443	450	inhibit	inhibit	B-VP	VBP	O	0	ROOT	O
T9	B-Entity	451	453	NF	NF	B-NP	NN	B-protein	8	NMOD	B-protein
T9	I-Entity	453	454	-	-	B-NP	HYPH	I-protein	8	NMOD	I-protein
T9	I-Entity	454	459	kappa	kappa	I-NP	NN	I-protein	8	NMOD	I-protein
T9	I-Entity	460	461	B	B	I-NP	NN	I-protein	8	NMOD	I-protein
O	O	462	472	activation	activation	I-NP	NN	O	3	OBJ	O
O	O	473	475	in	in	B-PP	IN	O	8	NMOD	O
O	O	476	484	response	response	B-NP	NN	O	9	PMOD	O
O	O	485	487	to	to	B-PP	TO	O	10	NMOD	O
O	O	488	493	these	these	B-NP	DT	O	13	NMOD	O
O	O	494	501	stimuli	stimulus	I-NP	NNS	O	11	PMOD	O
O	O	501	502	.	.	O	.	O	3	P	O

O	O	503	505	In	In	B-PP	IN	O	6	VMOD	O
O	O	506	510	this	this	B-NP	DT	O	3	NMOD	O
O	O	511	516	study	study	I-NP	NN	O	1	PMOD	O
O	O	516	517	,	,	O	,	O	6	P	O
O	O	518	520	we	we	B-NP	PRP	O	6	SUB	O
O	O	521	525	have	have	B-VP	VBP	O	0	ROOT	O
O	O	526	538	investigated	investigate	I-VP	VBN	O	6	VC	O
O	O	539	542	the	the	B-NP	DT	O	9	NMOD	O
O	O	543	550	effects	effect	I-NP	NNS	O	7	OBJ	O
O	O	551	553	of	of	B-PP	IN	O	9	NMOD	O
O	O	554	562	selenium	selenium	B-NP	NN	O	15	NMOD	O
O	O	562	563	,	,	O	,	O	15	P	O
O	O	564	566	an	an	B-NP	DT	O	15	NMOD	O
O	O	567	575	integral	integral	I-NP	JJ	O	15	NMOD	O
O	O	576	585	component	component	I-NP	NN	O	10	PMOD	O
O	O	586	588	of	of	B-PP	IN	O	15	NMOD	O
T1	B-Protein	589	600	glutathione	glutathione	B-NP	NN	B-protein	18	NMOD	B-protein
T1	I-Protein	601	611	peroxidase	peroxidase	I-NP	NN	I-protein	16	PMOD	I-protein
O	O	612	613	(	(	O	(	O	21	DEP	O
T2	B-Protein	613	616	GPX	GPX	B-NP	NN	B-protein	21	DEP	B-protein
O	O	616	617	)	)	O	)	O	18	NMOD	O
O	O	617	618	,	,	O	,	O	9	P	O
O	O	619	621	on	on	B-PP	IN	O	9	NMOD	O
T10	B-Entity	622	624	NF	NF	B-NP	NN	B-protein	28	NMOD	B-protein
T10	I-Entity	624	625	-	-	B-NP	HYPH	I-protein	28	NMOD	I-protein
T10	I-Entity	625	630	kappa	kappa	I-NP	NN	I-protein	28	NMOD	I-protein
T10	I-Entity	631	632	B	B	I-NP	NN	I-protein	28	NMOD	I-protein
O	O	633	643	activation	activation	I-NP	NN	O	23	PMOD	O
O	O	643	644	.	.	O	.	O	6	P	O

O	O	645	647	In	In	B-PP	IN	O	16	VMOD	O
O	O	648	656	selenium	selenium	B-NP	NN	O	11	NMOD	O
O	O	656	657	-	-	B-NP	HYPH	O	11	P	O
O	O	657	665	deprived	deprive	I-NP	VBN	O	11	NMOD	O
O	O	666	672	Jurkat	Jurkat	I-NP	NN	B-cell_line	7	NMOD	B-cell_line
O	O	673	676	and	and	I-NP	CC	O	7	NMOD	O
O	O	677	680	ESb	ESb	I-NP	NN	B-protein	11	NMOD	B-protein
O	O	680	681	-	-	B-NP	HYPH	O	11	P	O
O	O	681	682	L	L	I-NP	NN	B-cell_type	11	NMOD	B-cell_type
O	O	683	684	T	T	I-NP	NN	I-cell_type	11	NMOD	I-cell_type
O	O	685	696	lymphocytes	lymphocyte	I-NP	NNS	I-cell_type	1	PMOD	I-cell_type
O	O	696	697	,	,	O	,	O	16	P	O
O	O	698	713	supplementation	supplementation	B-NP	NN	O	16	SUB	O
O	O	714	716	of	of	B-PP	IN	O	13	NMOD	O
O	O	717	725	selenium	selenium	B-NP	NN	O	14	PMOD	O
O	O	726	729	led	lead	B-VP	VBD	O	0	ROOT	O
O	O	730	732	to	to	B-PP	TO	O	16	VMOD	O
O	O	733	734	a	a	B-NP	DT	O	20	NMOD	O
O	O	735	746	substantial	substantial	I-NP	JJ	O	20	NMOD	O
O	O	747	755	increase	increase	I-NP	NN	O	17	PMOD	O
O	O	756	758	of	of	B-PP	IN	O	20	NMOD	O
T3	B-Protein	759	762	GPX	GPX	B-NP	NN	B-protein	23	NMOD	B-protein
O	O	763	771	activity	activity	I-NP	NN	O	21	PMOD	O
O	O	771	772	.	.	O	.	O	16	P	O

O	O	773	781	Analysis	Analysis	B-NP	NN	O	5	SUB	O
O	O	782	784	of	of	B-PP	IN	O	1	NMOD	O
O	O	785	788	DNA	DNA	B-NP	NN	O	4	NMOD	O
O	O	789	796	binding	binding	I-NP	NN	O	2	PMOD	O
O	O	797	805	revealed	reveal	B-VP	VBD	O	0	ROOT	O
O	O	806	810	that	that	B-SBAR	IN	O	5	VMOD	O
T11	B-Entity	811	813	NF	NF	B-NP	NN	B-protein	11	NMOD	B-protein
T11	I-Entity	813	814	-	-	B-NP	HYPH	I-protein	11	NMOD	I-protein
T11	I-Entity	814	819	kappa	kappa	I-NP	NN	I-protein	11	NMOD	I-protein
T11	I-Entity	820	821	B	B	I-NP	NN	I-protein	11	NMOD	I-protein
O	O	822	832	activation	activation	I-NP	NN	O	16	SUB	O
O	O	833	835	in	in	B-PP	IN	O	11	NMOD	O
O	O	836	844	response	response	I-PP	NN	O	12	PMOD	O
O	O	845	847	to	to	I-PP	TO	O	13	NMOD	O
O	O	848	851	TNF	TNF	B-NP	NN	B-protein	14	PMOD	B-protein
O	O	852	855	was	be	B-VP	VBD	O	6	SBAR	O
O	O	856	869	significantly	significantly	I-VP	RB	O	16	VMOD	O
O	O	870	879	inhibited	inhibit	I-VP	VBN	O	16	VC	O
O	O	880	885	under	under	B-PP	IN	O	18	VMOD	O
O	O	886	891	these	these	B-NP	DT	O	21	NMOD	O
O	O	892	902	conditions	condition	I-NP	NNS	O	19	PMOD	O
O	O	902	903	.	.	O	.	O	5	P	O

O	O	904	912	Likewise	Likewise	B-ADVP	RB	O	18	VMOD	O
O	O	912	913	,	,	O	,	O	18	P	O
O	O	914	922	reporter	reporter	B-NP	NN	O	5	NMOD	O
O	O	923	927	gene	gene	I-NP	NN	O	5	NMOD	O
O	O	928	934	assays	assay	I-NP	NNS	O	18	SUB	O
O	O	935	940	using	use	B-VP	VBG	O	5	NMOD	O
O	O	941	951	luciferase	luciferase	B-NP	NN	B-DNA	8	NMOD	B-DNA
O	O	952	962	constructs	construct	I-NP	NNS	I-DNA	6	OBJ	I-DNA
O	O	963	969	driven	drive	B-VP	VBN	O	8	NMOD	O
O	O	970	972	by	by	B-PP	IN	O	9	VMOD	O
O	O	973	976	the	the	B-NP	DT	O	17	NMOD	O
T12	B-Entity	977	980	HIV	HIV	I-NP	NN	B-DNA	17	NMOD	B-DNA
T12	I-Entity	980	981	-	-	B-NP	HYPH	I-DNA	17	NMOD	I-DNA
T12	I-Entity	981	982	1	1	I-NP	CD	I-DNA	17	NMOD	I-DNA
T12	I-Entity	983	987	long	long	I-NP	JJ	I-DNA	17	NMOD	I-DNA
T12	I-Entity	988	996	terminal	terminal	I-NP	JJ	I-DNA	17	NMOD	I-DNA
T12	I-Entity	997	1003	repeat	repeat	I-NP	NN	I-DNA	10	PMOD	I-DNA
O	O	1004	1010	showed	show	B-VP	VBD	O	0	ROOT	O
O	O	1011	1012	a	a	B-NP	DT	O	20	NMOD	O
O	O	1013	1017	dose	dose	I-NP	NN	O	23	NMOD	O
O	O	1017	1018	-	-	B-NP	HYPH	O	23	NMOD	O
O	O	1018	1027	dependent	dependent	I-NP	JJ	O	23	NMOD	O
O	O	1028	1038	inhibition	inhibition	I-NP	NN	O	18	OBJ	O
O	O	1039	1041	of	of	B-PP	IN	O	23	NMOD	O
T13	B-Entity	1042	1044	NF	NF	B-NP	NN	B-protein	28	NMOD	B-protein
T13	I-Entity	1044	1045	-	-	B-NP	HYPH	I-protein	28	P	I-protein
T13	I-Entity	1045	1050	kappa	kappa	I-NP	NN	I-protein	28	NMOD	I-protein
T13	I-Entity	1051	1052	B	B	I-NP	NN	I-protein	31	NMOD	I-protein
O	O	1053	1063	controlled	controlled	I-NP	JJ	O	31	NMOD	O
O	O	1064	1068	gene	gene	I-NP	NN	O	31	NMOD	O
O	O	1069	1079	expression	expression	I-NP	NN	O	24	PMOD	O
O	O	1080	1082	by	by	B-PP	IN	O	23	NMOD	O
O	O	1083	1091	selenium	selenium	B-NP	NN	O	32	PMOD	O
O	O	1091	1092	.	.	O	.	O	18	P	O

O	O	1093	1096	The	The	B-NP	DT	O	2	NMOD	O
O	O	1097	1104	effects	effect	I-NP	NNS	O	5	SUB	O
O	O	1105	1107	of	of	B-PP	IN	O	2	NMOD	O
O	O	1108	1116	selenium	selenium	B-NP	NN	O	3	PMOD	O
O	O	1117	1121	were	be	B-VP	VBD	O	0	ROOT	O
O	O	1122	1130	specific	specific	B-ADJP	JJ	O	5	PRD	O
O	O	1131	1134	for	for	B-PP	IN	O	6	AMOD	O
T14	B-Entity	1135	1137	NF	NF	B-NP	NN	B-protein	11	NMOD	B-protein
T14	I-Entity	1137	1138	-	-	B-NP	HYPH	I-protein	11	NMOD	I-protein
T14	I-Entity	1138	1143	kappa	kappa	I-NP	NN	I-protein	11	NMOD	I-protein
T14	I-Entity	1144	1145	B	B	I-NP	NN	I-protein	7	PMOD	I-protein
O	O	1145	1146	,	,	O	,	O	5	P	O
O	O	1147	1152	since	since	B-SBAR	IN	O	5	VMOD	O
O	O	1153	1156	the	the	B-NP	DT	O	15	NMOD	O
O	O	1157	1165	activity	activity	I-NP	NN	O	23	SUB	O
O	O	1166	1168	of	of	B-PP	IN	O	15	NMOD	O
O	O	1169	1172	the	the	B-NP	DT	O	19	NMOD	O
O	O	1173	1186	transcription	transcription	I-NP	NN	B-protein	19	NMOD	B-protein
O	O	1187	1193	factor	factor	I-NP	NN	I-protein	21	NMOD	I-protein
T15	B-Entity	1194	1196	AP	AP	I-NP	NN	B-protein	21	NMOD	B-protein
T15	I-Entity	1196	1197	-	-	B-NP	HYPH	I-protein	16	PMOD	I-protein
T15	I-Entity	1197	1198	1	1	I-NP	CD	I-protein	21	NMOD	I-protein
O	O	1199	1202	was	be	B-VP	VBD	O	13	SBAR	O
O	O	1203	1206	not	not	I-VP	RB	O	23	VMOD	O
O	O	1207	1217	suppressed	suppress	I-VP	VBN	O	23	VC	O
O	O	1217	1218	.	.	O	.	O	5	P	O

O	O	1219	1224	These	These	B-NP	DT	O	2	NMOD	O
O	O	1225	1229	data	datum	I-NP	NNS	O	3	SUB	O
O	O	1230	1237	suggest	suggest	B-VP	VBP	O	0	ROOT	O
O	O	1238	1242	that	that	B-SBAR	IN	O	3	VMOD	O
O	O	1243	1251	selenium	selenium	B-NP	NN	O	6	NMOD	O
O	O	1252	1267	supplementation	supplementation	I-NP	NN	O	7	SUB	O
O	O	1268	1271	may	may	B-VP	MD	O	4	SBAR	O
O	O	1272	1274	be	be	I-VP	VB	O	7	VC	O
O	O	1275	1279	used	use	I-VP	VBN	O	8	VC	O
O	O	1280	1282	to	to	B-VP	TO	O	11	VMOD	O
O	O	1283	1291	modulate	modulate	I-VP	VB	O	7	VMOD	O
O	O	1292	1295	the	the	B-NP	DT	O	13	NMOD	O
O	O	1296	1306	expression	expression	I-NP	NN	O	24	NMOD	O
O	O	1307	1309	of	of	B-PP	IN	O	13	NMOD	O
T16,T17	B-Entity,B-Entity	1310	1312	NF	NF	B-NP	NN	O	20	NMOD	O
T16,T17	I-Entity,I-Entity	1312	1313	-	-	B-NP	HYPH	O	20	NMOD	O
T16,T17	I-Entity,I-Entity	1313	1318	kappa	kappa	I-NP	NN	B-DNA	20	NMOD	B-DNA
T16,T17	I-Entity,I-Entity	1319	1320	B	B	I-NP	NN	I-DNA	20	NMOD	I-DNA
T16	I-Entity	1321	1327	target	target	I-NP	NN	I-DNA	20	NMOD	I-DNA
T16	I-Entity	1328	1333	genes	gene	I-NP	NNS	I-DNA	14	PMOD	I-DNA
O	O	1334	1337	and	and	I-NP	CC	O	24	NMOD	O
O	O	1338	1341	HIV	HIV	I-NP	NN	O	23	NMOD	O
O	O	1341	1342	-	-	B-NP	HYPH	O	24	P	O
O	O	1342	1343	1	1	I-NP	CD	O	11	OBJ	O
O	O	1343	1344	.	.	O	.	O	3	P	O
